Go Pro
→ Is the fix for AI's runaway power problem your golden ticket? (From Eagle Publishing) (Ad)tc pixel Free NGNE Stock Alerts

Neurogene (NGNE) Financials

Neurogene logo
$42.84 +4.60 (+12.03%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$42.87 +0.03 (+0.07%)
As of 07/9/2026 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Neurogene

Annual Income Statements for Neurogene

This table shows Neurogene's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Consolidated Net Income / (Loss)		 -22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Net Income / (Loss) Continuing Operations		 -22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Total Pre-Tax Income 		-22 -37 -50 -32 -69 -33 -61 -55 -53 -75 -90
Total Operating Income		 -21 -38 -51 -33 -71 -34 -61 -57 -56 -83 -103
Total Gross Profit		 0.00 0.00 0.00 25 0.00 0.00 0.00 0.00 0.00 0.93 0.00
Total Revenue		 0.00 0.00 0.00 25 0.00 0.00 0.00 0.00 0.00 0.93 0.00
Operating Revenue		 - 0.00 - 25 - - - - 0.00 0.93 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 38 51 58 71 34 61 57 56 84 103
Selling, General & Admin Expense		 5.54 9.26 15 16 19 17 22 9.01 11 23 28
Research & Development Expense		 16 28 36 42 52 24 39 48 44 61 75
Total Other Income / (Expense), net		 -0.52 0.64 0.94 1.04 1.52 0.45 0.01 1.33 2.91 7.46 13
Interest Expense		 0.00 0.00 0.00 0.00 - - -0.02 0.00 0.01 0.01 0.01
Interest & Investment Income		 - - - - - - - 1.34 2.95 8.47 12
Other Income / (Expense), net		 -0.52 0.64 0.94 1.04 1.52 0.45 -0.01 -0.01 -0.03 -0.99 1.44
Basic Earnings per Share		 ($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($139.88) $0.00 ($4.28) ($4.24)
Weighted Average Basic Shares Outstanding		 12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 55.04M 394.53K 0.00 17.57M 21.33M
Diluted Earnings per Share		 ($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($139.88) $0.00 ($4.28) ($4.24)
Weighted Average Diluted Shares Outstanding		 12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 55.04M 394.53K 0.00 17.57M 21.33M
Weighted Average Basic & Diluted Shares Outstanding		 12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 42.49M 42.82M 12.85M 14.93M 15.57M

Quarterly Income Statements for Neurogene

This table shows Neurogene's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 2.38 -17 -18 -20 -20 -23 -22 -21 -25 -31
Consolidated Net Income / (Loss)		 -15 2.38 -17 -18 -20 -20 -23 -22 -21 -25 -31
Net Income / (Loss) Continuing Operations		 -15 2.38 -17 -18 -20 -20 -23 -22 -21 -25 -31
Total Pre-Tax Income 		-15 -14 -17 -19 -20 -20 -23 -23 -21 -23 -31
Total Operating Income		 -15 -15 -19 -20 -22 -22 -26 -26 -24 -28 -33
Total Gross Profit		 0.00 - 0.00 0.93 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.93 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 15 15 19 21 22 22 26 26 24 28 33
Selling, General & Admin Expense		 3.61 2.55 5.24 5.32 5.90 6.17 8.16 6.72 6.56 6.89 8.20
Research & Development Expense		 12 12 14 16 16 15 18 19 17 21 25
Total Other Income / (Expense), net		 0.64 0.76 1.72 1.50 1.82 1.85 3.27 2.85 2.70 4.30 2.42
Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.65 0.78 2.32 2.04 1.84 2.27 3.21 2.93 2.74 2.67 2.26
Other Income / (Expense), net		 -0.00 -0.02 -0.60 -0.53 -0.02 -0.41 0.07 -0.07 -0.04 1.63 0.15
Basic Earnings per Share		 ($32.67) $87.63 ($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39)
Weighted Average Basic Shares Outstanding		 446.26K 0.00 16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M
Diluted Earnings per Share		 ($32.67) $87.63 ($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39)
Weighted Average Diluted Shares Outstanding		 446.26K 0.00 16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M
Weighted Average Basic & Diluted Shares Outstanding		 9.40M 12.85M 12.98M 12.99M 14.85M 14.93M 14.26M 14.27M 15.49M 15.57M 15.80M

Annual Cash Flow Statements for Neurogene

This table details how cash moves in and out of Neurogene's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 25 -7.23 20 25 66 50 -50 11 67 -12 -33
Net Cash From Operating Activities		 -20 -30 -45 -32 -15 -25 -48 -53 -51 -71 -77
Net Cash From Continuing Operating Activities		 -20 -30 -45 -32 -15 -25 -48 -53 -51 -71 -77
Net Income / (Loss) Continuing Operations		 -22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Consolidated Net Income / (Loss)		 -22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Depreciation Expense		 - - 0.36 0.29 0.34 0.79 1.31 3.20 3.26 3.20 3.04
Amortization Expense		 - - - - 0.19 1.04 0.97 0.00 -0.07 -2.37 -4.49
Non-Cash Adjustments To Reconcile Net Income		 2.04 1.97 3.28 6.19 55 6.51 11 1.25 -15 6.58 12
Changes in Operating Assets and Liabilities, net		 -0.45 4.82 1.82 -6.47 -1.95 0.37 -0.01 -2.09 -3.35 -2.87 2.44
Net Cash From Investing Activities		 -48 -48 64 56 -0.69 -2.22 -3.26 -2.23 26 -125 14
Net Cash From Continuing Investing Activities		 -48 -48 64 56 -0.69 -2.22 -3.26 -2.23 26 -125 14
Purchase of Property, Plant & Equipment		 -0.03 -0.71 -0.49 - -0.88 -2.22 -3.26 -2.23 -0.32 -0.81 -1.18
Purchase of Investments		 -61 -106 -6.00 - - - 0.00 - 0.00 -198 -270
Sale and/or Maturity of Investments		 13 59 71 56 - - 0.00 0.00 5.00 74 285
Net Cash From Financing Activities		 93 71 0.42 0.57 82 77 0.73 67 92 184 30
Net Cash From Continuing Financing Activities		 93 71 0.42 0.57 82 77 0.73 67 92 184 30
Repayment of Debt		 0.00 -0.00 -0.02 -0.03 - - - -0.00 -0.03 -4.29 0.00
Repurchase of Common Equity		 -6.21 -4.69 - - -0.35 -0.36 - - - 0.00 -0.24
Payment of Dividends		 - - - - - - - - 0.00 -2.86 0.00
Issuance of Common Equity		 98 75 - - 81 72 0.37 0.00 92 190 30
Other Financing Activities, net		 1.12 0.44 0.44 0.60 1.55 5.62 0.36 0.07 0.17 1.62 0.21
Cash Interest Paid		 0.00 0.00 0.00 0.00 - - - 0.00 0.01 0.01 0.01

Quarterly Cash Flow Statements for Neurogene

This table details how cash moves in and out of Neurogene's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -13 103 1.76 -39 -44 70 -66 -12 12 33 20
Net Cash From Operating Activities		 -12 -17 -22 -16 -16 -17 -21 -19 -20 -17 -26
Net Cash From Continuing Operating Activities		 -12 -17 -22 -16 -16 -17 -21 -19 -20 -17 -26
Net Income / (Loss) Continuing Operations		 -15 2.38 -17 -18 -20 -20 -23 -22 -21 -25 -31
Consolidated Net Income / (Loss)		 -15 2.38 -17 -18 -20 -20 -23 -22 -21 -25 -31
Depreciation Expense		 0.82 0.82 0.81 0.80 0.80 0.79 0.75 0.75 0.76 0.78 0.85
Amortization Expense		 0.01 -0.09 -0.44 -0.31 -0.68 -0.95 -1.73 -1.46 -0.80 -0.49 -0.37
Non-Cash Adjustments To Reconcile Net Income		 0.05 -16 1.31 1.26 2.01 2.52 3.54 2.18 2.83 2.94 3.06
Changes in Operating Assets and Liabilities, net		 2.13 -4.07 -6.42 0.85 2.53 -0.35 -0.68 1.08 -1.34 4.09 1.27
Net Cash From Investing Activities		 -0.08 26 30 -24 -29 -103 -45 7.45 22 30 46
Net Cash From Continuing Investing Activities		 -0.08 26 30 -24 -29 -103 -45 7.45 22 30 46
Purchase of Property, Plant & Equipment		 -0.08 -0.13 -0.07 -0.46 -0.17 -0.12 -0.78 -0.15 -0.13 -0.13 -0.28
Purchase of Investments		 - - 0.00 -43 -38 -118 -89 -60 -77 -43 -83
Sale and/or Maturity of Investments		 - 5.00 30 20 8.75 16 45 68 100 73 130
Net Cash From Financing Activities		 -1.84 94 -6.52 0.40 0.13 190 0.00 0.05 9.71 21 0.20
Net Cash From Continuing Financing Activities		 -1.84 94 -6.52 0.40 0.13 190 0.00 0.05 9.71 21 0.20
Repayment of Debt		 -1.86 1.93 -4.29 - - -0.05 -0.02 -0.03 0.03 - -0.01
Other Financing Activities, net		 0.03 0.02 0.62 0.40 0.13 0.53 0.02 0.08 0.05 0.07 0.20
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Balance Sheets for Neurogene

This table presents Neurogene's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 113 154 110 78 147 211 163 109 223 336 289
Total Current Assets		 75 103 109 77 144 195 144 85 200 316 272
Cash & Equivalents		 40 32 52 77 143 193 142 82 148 137 104
Short-Term Investments		 35 71 56 - - - 0.00 0.00 49 176 165
Prepaid Expenses		 - - - - - - - 2.70 3.19 3.52 2.76
Plant, Property, & Equipment, net		 0.09 0.85 0.91 0.40 2.06 0.00 0.00 20 17 15 13
Total Noncurrent Assets		 38 50 0.60 0.05 1.37 16 19 4.43 5.05 4.39 4.04
Noncurrent Note & Lease Receivables		 - - - - - - - 0.09 0.10 0.07 0.02
Other Noncurrent Operating Assets		 - 0.00 0.60 0.05 0.80 16 19 4.34 4.95 4.31 4.02
Total Liabilities & Shareholders' Equity		 113 154 110 78 147 211 163 109 223 336 289
Total Liabilities		 4.92 9.72 11 4.95 5.34 19 20 11 37 25 24
Total Current Liabilities		 4.79 9.52 11 4.63 4.74 7.89 8.64 6.65 23 15 16
Accounts Payable		 4.79 9.52 11 4.62 4.13 7.18 7.42 0.63 2.60 1.34 1.95
Accrued Expenses		 - - - - - - - 5.32 17 9.73 11
Other Current Liabilities		 - - - 0.01 0.62 0.71 1.22 0.70 2.88 4.09 3.70
Total Noncurrent Liabilities		 0.13 0.20 0.49 0.32 0.59 11 12 3.99 14 10 7.31
Capital Lease Obligations		 - - - 0.01 - 0.11 - 0.07 0.07 0.03 0.01
Other Noncurrent Operating Liabilities		 0.13 0.20 0.49 - 0.59 11 12 3.92 14 10 7.30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - - - 0.00 - - 0.00
Total Equity & Noncontrolling Interests		 108 145 99 73 142 191 143 -146 186 310 265
Total Preferred & Common Equity		 108 145 99 73 142 191 143 -146 186 310 265
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 108 145 99 73 142 191 143 -146 186 310 265
Common Stock		 220 293 297 303 441 524 536 5.10 373 573 618
Retained Earnings		 -111 -148 -199 -230 -300 -333 -393 -151 -187 -262 -353

Quarterly Balance Sheets for Neurogene

This table presents Neurogene's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 90 195 180 164 315 297 288 263
Total Current Assets		 80 174 159 144 296 279 271 247
Cash & Equivalents		 25 150 111 67 71 59 71 124
Short-Term Investments		 53 19 43 72 222 216 194 119
Prepaid Expenses		 - 4.61 5.24 4.65 3.80 4.47 5.11 3.57
Plant, Property, & Equipment, net		 0.48 16 16 16 15 14 13 13
Total Noncurrent Assets		 9.21 4.73 4.61 4.41 4.10 4.08 3.83 3.89
Noncurrent Note & Lease Receivables		 - 0.09 0.10 0.08 0.06 0.05 0.03 0.02
Other Noncurrent Operating Assets		 9.21 4.65 4.51 4.32 4.04 4.04 3.80 3.88
Total Liabilities & Shareholders' Equity		 90 195 180 164 315 297 288 263
Total Liabilities		 14 25 25 27 24 24 22 25
Total Current Liabilities		 5.21 12 13 16 14 15 15 19
Accounts Payable		 3.66 1.52 1.72 1.68 3.06 2.06 1.54 4.69
Accrued Expenses		 - 6.82 7.14 10 6.85 9.10 9.42 11
Other Current Liabilities		 1.55 3.47 4.21 3.68 4.18 4.28 3.74 3.05
Total Noncurrent Liabilities		 9.14 13 12 11 9.41 8.62 7.58 6.49
Capital Lease Obligations		 0.01 - 0.05 0.04 0.02 0.01 0.01 0.00
Other Noncurrent Operating Liabilities		 9.13 13 12 11 9.40 8.61 7.58 6.49
Commitments & Contingencies		 - - - - - - - 0.00
Total Equity & Noncontrolling Interests		 75 171 155 137 292 273 266 238
Total Preferred & Common Equity		 75 171 155 137 292 273 266 238
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 75 171 155 137 292 273 266 238
Common Stock		 547 375 378 380 577 580 593 621
Retained Earnings		 -472 -204 -223 -243 -285 -307 -328 -384

Annual Metrics And Ratios for Neurogene

This table displays calculated financial ratios and metrics derived from Neurogene's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 17,211,986.00 23,423,150.00 23,464,930.00 23,537,368.00 38,332,943.00 41,894,382.00 42,428,134.00 42,594,602.00 9,397,901.00 - 15,489,800.00
DEI Adjusted Shares Outstanding		 17,211,986.00 23,423,150.00 23,464,930.00 23,537,368.00 38,332,943.00 41,894,382.00 42,428,134.00 42,594,602.00 9,397,901.00 - 15,489,800.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.27 -1.58 -2.14 -1.34 -1.81 -0.79 -1.43 -1.30 -3.86 - -5.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 -2.28% -69.26% -34.64% 37.19% -120.23% 54.35% -85.76% 8.74% 1.70% -59.00% -24.85%
EBIT Growth		 7.28% -69.26% -35.62% 37.06% -119.89% 52.08% -82.44% 6.90% 1.62% -51.36% -21.88%
NOPAT Growth		 4.63% -76.41% -35.79% 36.18% -117.51% 52.47% -79.96% 6.89% 1.65% -48.62% -25.09%
Net Income Growth		 9.02% -69.27% -35.62% 37.06% -119.86% 52.08% -82.38% 9.07% 34.20% -106.91% -20.24%
EPS Growth		 37.09% -13.29% -9.18% 37.38% -91.79% 75.10% -71.88% -12,616.36% 100.00% 0.00% 0.93%
Operating Cash Flow Growth		 -15.91% -49.13% -47.95% 29.39% 51.25% -59.64% -93.52% -11.07% 2.65% -37.30% -9.31%
Free Cash Flow Firm Growth		 -9.13% -45.93% -56.15% 20.67% -89.01% 54.71% -85.50% -26.56% 80.00% -498.92% -4.97%
Invested Capital Growth		 8.74% -86.75% -8.97% 53.79% 66.92% 12.38% 132.22% 4,099.50% -166.39% 81.89% -105.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 10.02% -17.76% -10.32% 27.16% -4.06% -16.06% -4.22% 7.36% -7.63% -10.71% -3.53%
EBIT Q/Q Growth		 10.02% -17.76% -11.12% 26.49% -4.86% -15.79% -4.37% 5.88% -5.91% -9.32% -4.06%
NOPAT Q/Q Growth		 9.45% -18.48% -11.01% 25.61% -4.50% -14.54% -4.36% 5.83% -5.83% -8.94% -6.18%
Net Income Q/Q Growth		 10.00% -17.76% -11.13% 26.49% -4.85% -15.79% -4.34% 6.90% 27.04% -41.12% -6.13%
EPS Q/Q Growth		 5.98% -12.64% -10.88% 26.78% -0.78% 0.00% -5.77% -2,509.70% 100.00% -105.07% -2.91%
Operating Cash Flow Q/Q Growth		 11.89% -20.01% -6.19% 5.48% 25.03% -22.99% -6.59% -12.77% 2.24% -0.75% 0.09%
Free Cash Flow Firm Q/Q Growth		 11.03% -21.99% -3.41% -5.67% 9.85% -24.61% -6.40% -36.69% 67.83% -22.05% -0.60%
Invested Capital Q/Q Growth		 -33.57% -16.60% -64.16% 57.54% -296.64% -52.10% 784.48% 1,464.32% -238.78% -30.13% -3,108.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% -125.17% 0.00% 0.00% 0.00% 0.00% 0.00% -9,010.27% 0.00%
Operating Margin		 0.00% 0.00% 0.00% -130.50% 0.00% 0.00% 0.00% 0.00% 0.00% -8,930.27% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% -126.32% 0.00% 0.00% 0.00% 0.00% 0.00% -9,099.78% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -126.34% 0.00% 0.00% 0.00% 0.00% 0.00% -8,123.68% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 68.95% 99.24% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.01% 100.01% 100.00% 100.00% 99.97% 97.64% 94.72% 89.96% 88.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.24% -29.24% -41.21% -36.82% -64.79% -19.99% -36.33% -45.71% -25.52% -30.28% -31.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,112.75% -654.25% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -33.61% 0.00% 0.00% 0.00% 0.00% 0.00% -30.15% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -33.61% 0.00% 0.00% 0.00% 0.00% 0.00% -26.92% 0.00%
Return on Common Equity (ROCE)		 -30.24% -29.24% -41.21% -36.82% -64.79% -19.99% -36.33% 0.54% -3.61% -30.28% -31.41%
Return on Equity Simple (ROE_SIMPLE)		 -20.16% -25.58% -50.75% -43.46% -49.01% -17.40% -42.48% 37.87% -19.52% -24.21% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -26 -36 -23 -50 -24 -42 -40 -39 -58 -72
NOPAT Margin		 0.00% 0.00% 0.00% -91.35% 0.00% 0.00% 0.00% 0.00% 0.00% -6,251.19% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.99% -8.01% -11.03% -9.46% -17.97% -5.76% -10.87% -13.93% 1.86% -6.80% -6.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -20.91% -18.63% -27.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 63.34% 0.00% 0.00% 0.00% 0.00% 0.00% 2,444.65% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 167.16% 0.00% 0.00% 0.00% 0.00% 0.00% 6,585.62% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 230.50% 0.00% 0.00% 0.00% 0.00% 0.00% 9,030.27% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -37 -50 -32 -69 -33 -61 -57 -56 -84 -102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -37 -50 -31 -69 -31 -58 -53 -52 -83 -103
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 1.66
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 1.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 434.14 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.44 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.05 -1.07 -1.08 -1.03 -1.01 -1.00 -0.93 -0.98 -1.03 -1.01
Leverage Ratio		 1.07 1.06 1.09 1.10 1.05 1.07 1.12 1.13 1.17 1.12 1.09
Compound Leverage Factor		 1.07 1.06 1.09 1.10 1.05 1.07 1.12 1.10 1.10 1.01 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.01% 0.00% 0.06% 0.00% 0.07% 0.03% 0.01% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.01% 0.00% 0.06% 0.00% 0.07% 0.03% 0.01% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 247.60% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 99.99% 100.00% 99.94% 100.00% -147.67% 99.97% 99.99% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 2.46 0.00 6.12 0.00 1.54 3.76 3.75 2.60
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 3.37 0.00 8.15 0.00 2.07 5.07 5.40 3.72
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.66 9.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 101.19% 85.85% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.61 10.87 9.93 16.68 30.28 24.66 16.67 12.74 8.72 20.84 16.56
Quick Ratio		 15.54 10.83 9.87 16.63 30.17 24.41 16.50 12.33 8.58 20.61 16.39
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -22 -35 -28 -53 -24 -44 -56 -11 -67 -70
Operating Cash Flow to CapEx		 -77,953.85% -4,239.27% -9,052.23% 0.00% -1,751.31% -1,107.48% -1,457.49% -2,368.79% -16,019.31% -8,738.00% -6,523.50%
Free Cash Flow to Firm to Interest Expense		 0.00 -22,430.50 -8,756.58 -6,946.20 0.00 0.00 0.00 -27,918.45 -930.68 -5,573.96 -14,042.52
Operating Cash Flow to Interest Expense		 0.00 -30,226.00 -11,179.50 -7,894.25 0.00 0.00 0.00 -26,412.00 -4,285.17 -5,883.58 -15,434.60
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -30,939.00 -11,303.00 -7,882.00 0.00 0.00 0.00 -27,527.00 -4,311.92 -5,950.92 -15,671.20
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 38.31 0.00 0.00 0.00 0.00 0.00 0.06 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.52 -8.44 -9.20 -4.25 -1.41 -1.23 0.40 17 -11 -2.00 -4.12
Invested Capital Turnover		 0.00 0.00 0.00 -3.72 0.00 0.00 0.00 0.00 0.00 -0.14 0.00
Increase / (Decrease) in Invested Capital		 0.43 -3.92 -0.76 4.95 2.84 0.17 1.63 16 -28 9.06 -2.12
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 89 170
Market Capitalization		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 402 439
Book Value per Share		 $6.30 $6.18 $4.21 $3.09 $3.70 $4.56 $3.37 ($3.42) $19.79 $20.89 $17.10
Tangible Book Value per Share		 $6.30 $6.18 $4.21 $3.09 $3.68 $4.56 $3.36 ($3.42) $19.79 $20.89 $17.10
Total Capital		 108 145 99 73 142 191 143 99 186 310 265
Total Debt		 0.00 0.00 0.00 0.01 0.00 0.11 0.00 0.07 0.07 0.03 0.01
Total Long-Term Debt		 0.00 0.00 0.00 0.01 0.00 0.11 0.00 0.07 0.07 0.03 0.01
Net Debt		 -113 -153 -108 -77 -143 -192 -142 -82 -197 -312 -269
Capital Expenditures (CapEx)		 0.03 0.71 0.49 -0.05 0.88 2.22 3.26 2.23 0.32 0.81 1.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.48 -9.09 -10 -4.39 -4.24 -5.92 -7.11 -3.95 -20 -12 -14
Debt-free Net Working Capital (DFNWC)		 70 94 98 73 139 187 135 78 177 301 255
Net Working Capital (NWC)		 70 94 98 73 139 187 135 78 177 301 255
Net Nonoperating Expense (NNE)		 6.92 11 14 8.75 20 9.67 18 16 -2.59 17 18
Net Nonoperating Obligations (NNO)		 -113 -153 -108 -77 -143 -192 -142 -82 -197 -312 -269
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.36 0.29 0.53 1.82 2.28 3.20 3.19 0.83 -1.44
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -17.56% 0.00% 0.00% 0.00% 0.00% 0.00% -1,258.27% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.15% 0.00% 0.00% 0.00% 0.00% 0.00% 32,515.24% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 290.15% 0.00% 0.00% 0.00% 0.00% 0.00% 32,515.24% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($1.04) $0.00 ($4.28) ($4.24)
Adjusted Weighted Average Basic Shares Outstanding		 17.21M 23.42M 23.49M 23.54M 38.37M 42.33M 55.04M 55.22M 0.00 17.57M 21.33M
Adjusted Diluted Earnings per Share		 ($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($1.04) $0.00 ($4.28) ($4.24)
Adjusted Weighted Average Diluted Shares Outstanding		 17.21M 23.42M 23.49M 23.54M 38.37M 42.33M 55.04M 55.22M 0.00 17.57M 21.33M
Adjusted Basic & Diluted Earnings per Share		 ($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 42.49M 42.82M 12.85M 14.93M 15.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -26 -36 -23 -50 -29 -42 -40 -39 -58 -72
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -91.35% 0.00% 0.00% 0.00% 0.00% 0.00% -6,251.19% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -126.34% 0.00% 0.00% 0.00% 0.00% 0.00% -8,185.73% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -37,001.00 -12,544.75 -7,895.25 0.00 0.00 0.00 -28,262.00 -4,634.25 -7,014.42 -20,378.60
NOPAT to Interest Expense		 0.00 -26,351.50 -8,945.83 -5,709.20 0.00 0.00 0.00 -19,780.95 -3,242.34 -4,818.63 -14,465.92
EBIT Less CapEx to Interest Expense		 0.00 -37,714.00 -12,668.25 -7,883.00 0.00 0.00 0.00 -29,377.00 -4,661.00 -7,081.75 -20,615.20
NOPAT Less CapEx to Interest Expense		 0.00 -27,064.50 -9,069.33 -5,696.95 0.00 0.00 0.00 -20,895.95 -3,269.09 -4,885.96 -14,702.52
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.80% 0.00%
Augmented Payout Ratio		 -28.41% -12.68% 0.00% 0.00% -0.51% -1.07% 0.00% 0.00% 0.00% -3.80% -0.27%

Quarterly Metrics And Ratios for Neurogene

This table displays calculated financial ratios and metrics derived from Neurogene's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 44,021,429.00 9,397,901.00 12,852,985.00 12,980,289.00 12,993,613.00 - 14,929,566.00 14,262,066.00 14,271,916.00 15,489,800.00 15,574,293.00
DEI Adjusted Shares Outstanding		 44,021,429.00 9,397,901.00 12,852,985.00 12,980,289.00 12,993,613.00 - 14,929,566.00 14,262,066.00 14,271,916.00 15,489,800.00 15,574,293.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.33 0.25 -1.32 -1.42 -1.56 - -1.52 -1.54 -1.47 -1.60 -1.99
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -18.21% -36.04% -55.50% -56.69% -42.05% -57.46% -41.23% -33.13% -8.15% -19.05% -21.91%
EBIT Growth		 -11.68% -26.64% -48.65% -64.02% -45.83% -48.65% -33.38% -26.55% -7.39% -21.30% -28.41%
NOPAT Growth		 -11.83% -26.23% -44.07% -59.84% -45.74% -46.01% -38.02% -29.54% -7.29% -27.98% -28.67%
Net Income Growth		 -11.51% 121.51% -37.98% -55.92% -38.69% -918.88% -33.84% -19.06% -3.64% -26.76% -36.59%
EPS Growth		 -2,668.64% 163.44% 96.46% 95.91% 96.36% -101.14% -8.00% 3.67% 16.81% -12.00% -28.70%
Operating Cash Flow Growth		 54.04% 6.49% -59.72% -70.40% -34.54% -3.09% 4.05% -22.46% -25.34% 0.38% -25.73%
Free Cash Flow Firm Growth		 -2.94% 171.29% -233.13% -191.89% -100.42% -238.42% 2.18% 10.69% -6.27% 28.89% -16.33%
Invested Capital Growth		 -167.35% -166.39% 159.84% 146.85% 52.86% 81.89% -163.50% -208.00% 108.90% -105.64% -582.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -20.72% 9.76% -35.47% -6.18% -9.44% 0.50% -24.74% 0.46% 11.10% -7.25% -27.73%
EBIT Q/Q Growth		 -20.82% 3.11% -31.40% -6.64% -7.41% 1.23% -21.07% -0.60% 8.85% -8.64% -28.17%
NOPAT Q/Q Growth		 -20.82% 3.19% -27.46% -7.22% -10.16% 3.01% -20.49% -0.63% 8.75% -15.68% -21.14%
Net Income Q/Q Growth		 -22.91% 116.35% -810.07% -9.28% -9.33% 3.48% -16.06% 2.79% 4.83% -18.05% -25.06%
EPS Q/Q Growth		 -22.45% 368.23% -101.14% -9.00% -9.17% 15.97% -8.00% 2.78% 5.71% -13.13% -24.11%
Operating Cash Flow Q/Q Growth		 -5.43% -46.72% -27.56% 26.59% 2.07% -12.41% -18.74% 6.32% -0.24% 10.66% -49.86%
Free Cash Flow Firm Q/Q Growth		 -41.67% 302.44% -194.50% -7.70% 2.72% -39.82% 33.22% 1.67% -15.76% 6.44% -9.24%
Invested Capital Q/Q Growth		 -31.73% -238.78% 111.24% -6.59% -232.53% -30.13% 60.58% -58.86% 110.92% -3,108.03% -30.91%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% -2,181.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% -2,176.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% -2,234.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -1,999.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% -17.06% 99.16% 99.23% 99.30% 99.27% 100.00% 94.78% 99.29% 106.50% 100.00%
Interest Burden Percent		 95.76% 94.73% 88.05% 90.17% 91.72% 89.66% 87.61% 88.81% 88.52% 89.68% 93.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -37.88% -25.52% -32.50% -40.59% -50.08% -30.28% 0.00% -39.41% -42.25% -31.41% -37.25%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -3,718.00% -4,461.92% 0.00% 0.00% 0.00% 0.00% -50,944.53% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -15.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -13.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -37.88% -3.61% -32.50% -40.59% -50.08% -30.28% 0.00% -39.41% -42.25% -31.41% -37.25%
Return on Equity Simple (ROE_SIMPLE)		 -45.54% 0.00% -23.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -10 -13 -14 -16 -15 -18 -18 -17 -19 -23
NOPAT Margin		 0.00% 0.00% 0.00% -1,523.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.23% 9.10% -2.99% -3.73% -4.31% -1.75% -1.95% -1.76% -2.12% -1.88% -2.83%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.54% -7.70% -9.09% -11.30% -4.85% -6.22% -6.68% -6.27% -7.28% -9.82%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 574.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 1,702.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 2,276.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -15 -19 -21 -22 -22 -26 -26 -24 -26 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -14 -19 -20 -22 -22 -27 -27 -24 -26 -33
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.04 3.98 5.18 1.29 0.84 1.15 1.38 1.66 1.89
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.04 3.98 5.18 1.29 0.84 1.15 1.38 1.66 1.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 666.49 769.04 434.14 265.80 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 555.36 398.15 0.00 0.00 0.00 0.00 740.48 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 500.16 618.82 96.44 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.98 -1.00 -1.01 -1.02 -1.03 -1.00 -1.00 -1.00 -1.01 -1.01
Leverage Ratio		 1.20 1.17 1.17 1.17 1.19 1.12 1.10 1.11 1.12 1.09 1.09
Compound Leverage Factor		 1.14 1.10 1.03 1.05 1.09 1.01 0.97 0.99 0.99 0.97 1.02
Debt to Total Capital		 0.01% 0.03% 0.00% 0.03% 0.03% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.01% 0.03% 0.00% 0.03% 0.03% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.97% 100.00% 99.97% 99.97% 99.99% 99.99% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.05 3.76 0.00 2.28 1.85 3.75 3.23 2.80 2.66 2.60 2.23
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.95 5.07 0.00 3.19 2.62 5.40 4.66 4.10 3.90 3.72 3.14
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 20.22 13.78 14.41 9.27 5.82 7.18 9.07 10.17 9.22
Noncontrolling Interest Sharing Ratio		 0.00% 85.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.33 8.72 14.74 12.17 9.09 20.84 21.03 18.07 18.39 16.56 13.08
Quick Ratio		 15.06 8.58 14.35 11.77 8.80 20.61 20.76 17.78 18.04 16.39 12.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.61 17 -16 -18 -17 -24 -16 -16 -18 -17 -19
Operating Cash Flow to CapEx		 0.00% -13,259.38% -33,307.69% -3,455.00% -9,319.76% -15,082.76% -2,663.33% -13,150.00% -15,360.63% -13,616.41% -9,295.02%
Free Cash Flow to Firm to Interest Expense		 -2,152.08 5,808.97 -5,489.43 -4,433.95 -5,751.00 -12,061.20 -8,054.65 -15,839.70 -18,335.60 -17,154.00 0.00
Operating Cash Flow to Interest Expense		 -1,067.25 -5,657.33 -7,216.67 -3,973.25 -5,188.00 -8,748.00 -10,387.00 -19,462.00 -19,508.00 -17,429.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,067.25 -5,700.00 -7,238.33 -4,088.25 -5,243.67 -8,806.00 -10,777.00 -19,610.00 -19,635.00 -17,557.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.11 0.11 0.06 0.06 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.27 -11 1.24 1.16 -1.54 -2.00 -0.79 -1.26 0.14 -4.12 -5.40
Invested Capital Turnover		 0.00 0.00 0.00 -1.40 -0.38 -0.14 4.07 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.05 -28 3.32 3.64 1.73 9.06 -2.03 -2.42 1.68 -2.12 -4.61
Enterprise Value (EV)		 0.00 0.00 691 463 572 89 -47 40 101 170 207
Market Capitalization		 0.00 0.00 860 617 711 402 246 315 367 439 450
Book Value per Share		 $1.71 $19.79 $13.29 $11.94 $10.58 $20.89 $19.54 $19.16 $18.61 $17.10 $15.27
Tangible Book Value per Share		 $1.71 $19.79 $13.29 $11.94 $10.58 $20.89 $19.54 $19.16 $18.61 $17.10 $15.27
Total Capital		 75 186 171 155 137 310 292 273 266 265 238
Total Debt		 0.01 0.07 0.00 0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.00
Total Long-Term Debt		 0.01 0.07 0.00 0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.00
Net Debt		 -79 -197 -170 -154 -139 -312 -293 -275 -265 -269 -243
Capital Expenditures (CapEx)		 0.00 0.13 0.07 0.46 0.17 0.12 0.78 0.15 0.13 0.13 0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.83 -20 -7.21 -7.83 -11 -12 -10 -11 -9.60 -14 -15
Debt-free Net Working Capital (DFNWC)		 75 177 162 146 128 301 282 264 256 255 228
Net Working Capital (NWC)		 75 177 162 146 128 301 282 264 256 255 228
Net Nonoperating Expense (NNE)		 3.92 -13 3.78 4.40 4.69 4.46 4.50 3.76 4.29 5.46 7.59
Net Nonoperating Obligations (NNO)		 -79 -197 -170 -154 -139 -312 -293 -275 -265 -269 -243
Total Depreciation and Amortization (D&A)		 -0.32 0.72 0.38 0.49 0.12 -0.16 -0.99 -0.71 -0.04 0.29 0.48
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -846.38% -1,204.97% -1,258.27% -1,113.30% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 15,792.00% 13,821.30% 32,515.24% 30,519.35% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 15,792.00% 13,821.30% 32,515.24% 30,519.35% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.41) $87.63 ($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39)
Adjusted Weighted Average Basic Shares Outstanding		 11.10M 0.00 16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M
Adjusted Diluted Earnings per Share		 ($0.41) $87.63 ($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39)
Adjusted Weighted Average Diluted Shares Outstanding		 11.10M 0.00 16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.40M 12.85M 12.98M 12.99M 14.85M 14.93M 14.26M 14.27M 15.49M 15.57M 15.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -10 -13 -14 -16 -15 -18 -18 -17 -19 -23
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -1,523.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -2,014.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3,805.75 -4,916.67 -6,460.33 -5,166.75 -7,399.67 -10,963.00 -12,925.50 -26,155.00 -23,840.00 -25,899.00 0.00
NOPAT to Interest Expense		 -2,663.33 -3,437.70 -4,381.77 -3,523.45 -5,175.33 -7,529.20 -9,071.65 -18,256.70 -16,658.60 -19,271.00 0.00
EBIT Less CapEx to Interest Expense		 -3,805.75 -4,959.33 -6,482.00 -5,281.75 -7,455.33 -11,021.00 -13,315.50 -26,303.00 -23,967.00 -26,027.00 0.00
NOPAT Less CapEx to Interest Expense		 -2,663.33 -3,480.37 -4,403.43 -3,638.45 -5,231.00 -7,587.20 -9,461.65 -18,404.70 -16,785.60 -19,399.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -6.97% -6.00% -5.36% -3.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -6.97% -6.00% -5.36% -3.80% 0.00% 0.00% 0.00% -0.27% 0.00%

Financials Breakdown Chart

Key Financial Trends

Neurogene (NASDAQ: NGNE) is still a pre-revenue biotech story, and the latest quarter shows the company remains deeply dependent on its cash reserves and investment portfolio to fund operations. For Q1 2026, Neurogene reported no revenue, a net loss of $30.9 million, and negative operating cash flow of $26.1 million. On the positive side, the balance sheet remains very strong, with $243.2 million in cash and short-term investments and only $25.4 million in total liabilities.

Here are the key takeaways from the last several quarters:

  • Neurogene ended Q1 2026 with $243.2 million in cash and short-term investments, giving it a sizable liquidity cushion.
  • Total liabilities were only $25.4 million in Q1 2026 versus $263.1 million in total assets, which keeps the balance sheet conservatively positioned.
  • The company generated $46.2 million of net cash from investing activities in Q1 2026, helped by $130.0 million of investment maturities/sales.
  • Cash and investments have remained well above near-term liabilities throughout the last year, suggesting the company is not in immediate funding stress.
  • Financing activity was modestly positive in Q1 2026, with $195,000 of net cash from financing activities.
  • Revenue remains at $0 across all recent quarters shown, so the business is still in a development-stage, clinical-stage profile.
  • The company continues to post large quarterly operating losses, but losses have generally trended in the $20 million to $33 million range over the past year.
  • Operating expenses rose in Q1 2026 versus Q4 2025, with R&D increasing to $25.2 million from $20.6 million and SG&A increasing to $8.2 million from $6.9 million.
  • Interest and investment income remains an important offset, generating $2.3 million in Q1 2026 and $2.7 million in Q4 2025.
  • Operating cash flow was negative $26.1 million in Q1 2026, indicating the core business is still burning cash.
  • The Q1 2026 net loss widened to $30.9 million from $24.7 million in Q4 2025.
  • Cash and equivalents fell to $124.2 million in Q1 2026 from $141.0 million in Q4 2025, even after considering short-term investments.
  • Retained earnings remain deeply negative at $383.6 million, reflecting accumulated losses over time.
  • Share count has continued to rise over time, with weighted average basic shares up to 22.3 million in Q1 2026 from 21.3 million in Q4 2025 and much lower levels a year earlier.

Longer-term trend: Neurogene’s quarterly losses have generally widened from early 2024 into 2025 and 2026 as operating expenses increased, especially R&D. That said, the company has preserved a strong cash position by managing investments aggressively and, in some periods, raising capital through financing activity. For retail investors, the main story remains clinical progress versus ongoing cash burn.

Bottom line: Neurogene does not yet have revenue to offset expenses, so valuation will continue to depend on pipeline execution. The good news is that the company appears well-funded for now. The risk is that ongoing losses and rising operating expenses will keep pressure on cash over time if clinical milestones do not translate into future commercialization opportunities.

07/10/26 03:08 AM ETAI Generated. May Contain Errors.

Neurogene Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neurogene's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Neurogene's net income appears to be on an upward trend, with a most recent value of -$90.35 million in 2025, rising from -$21.86 million in 2015. The previous period was -$75.14 million in 2024. Find out what analysts predict for Neurogene in the coming months.

Neurogene's total operating income in 2025 was -$103.33 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $103.33 million

Over the last 10 years, Neurogene's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Neurogene's total liabilities were at $23.72 million at the end of 2025, a 6.5% decrease from 2024, and a 381.8% increase since 2015.

In the past 10 years, Neurogene's cash and equivalents has ranged from $32.30 million in 2016 to $192.56 million in 2020, and is currently $103.85 million as of their latest financial filing in 2025.

Over the last 10 years, Neurogene's book value per share changed from 6.30 in 2015 to 17.10 in 2025, a change of 171.5%.


Related Companies

Financial statements for NASDAQ:NGNE last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Move your money (NOT into the next AI IPO)
While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...
Stansberry Research | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel